Dr. Dave Fromm & Dr. Robert Lin, Cepheid
April 14, 6 pm (Meet and greet with food at 5:30 pm)
Blum Hall B100
New Commercial Platforms for Next-generation Molecular Diagnostic Testing
Cepheid is a leader in molecular diagnostic testing, featuring the GeneXpert system: a disposable, single-use assay cartridge processed in a fully automated instrument. Each GeneXpert assay features fully integrated sample preparation and processing,generating analytical test results using quantitative polymerase chain reaction (qPCR). The GeneXpert system is the world’s most popular molecular diagnostics instrument, and is currently used in both central laboratory and point-of-care settings, where Cepheid is a leader in the PoC diagnosis of tuberculosis.
We will discuss two next-generation platforms that represent the future of high-throughput, automated molecular diagnostics at Cepheid. First, the Honeycomb module enables simultaneous, parallel qPCR measurement of highly-multiplexed targets for panel assay testing. Second, we will present the GeneXpert Omni, a compact, low-cost, fully integrated instrument that will process existing GeneXpert cartridges in non-standard laboratory PoC environments. Omni features a simplified, ruggedized design to make qPCR technology accessible to health workers in the field with limited training and full Cloud connectivity to provide real-time system monitoring and disease surveillance.
April 14, 6 pm (Meet and greet with food at 5:30 pm)
Blum Hall B100
New Commercial Platforms for Next-generation Molecular Diagnostic Testing
Cepheid is a leader in molecular diagnostic testing, featuring the GeneXpert system: a disposable, single-use assay cartridge processed in a fully automated instrument. Each GeneXpert assay features fully integrated sample preparation and processing,generating analytical test results using quantitative polymerase chain reaction (qPCR). The GeneXpert system is the world’s most popular molecular diagnostics instrument, and is currently used in both central laboratory and point-of-care settings, where Cepheid is a leader in the PoC diagnosis of tuberculosis.
We will discuss two next-generation platforms that represent the future of high-throughput, automated molecular diagnostics at Cepheid. First, the Honeycomb module enables simultaneous, parallel qPCR measurement of highly-multiplexed targets for panel assay testing. Second, we will present the GeneXpert Omni, a compact, low-cost, fully integrated instrument that will process existing GeneXpert cartridges in non-standard laboratory PoC environments. Omni features a simplified, ruggedized design to make qPCR technology accessible to health workers in the field with limited training and full Cloud connectivity to provide real-time system monitoring and disease surveillance.